

CCR MANUSCRIPT NOTIFICATION (MAY 2011)

Laboratory of Immune Cell Biology - Jonathan Ashwell, M.D.

There were no submissions reported this month.

Vaccine Branch - Jay Berzofsky, M.D., Ph.D.

Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, **Yarchoan R, Terabe M**, Sui Y, and **Berzofsky JA**: IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. *J Leuk. Biol.* In press. (VB)

Gordon SN, Cecchinato V, Andresen V, Heraud JM, Hryniewicz A, Parks RW, Venzon D, Chung HK, Karpova T, McNally J, Silvera P, Reimann KA, Matsui H, Kanehara T, Shinmura Y, Yokote H, and **Franchini G**: Smallpox vaccine safety is dependent on T cells and not B cells. *Vaccine.* 29(14): 2619-2625, 2011. (VB)

Strbo N, Vaccari M, Pahwa S, Kolber MA, Fisher E, Gonzalez L, Doster MN, Hryniewicz A, **Felber BK, Pavlakis GN, Franchini G**, and Podack ER: Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. *Vaccine.* 29(14): 2619-2625, 2011. (VB)

Andresen V, Pise-Masison CA, Sinha-Datta U, Bellon M, Valeri V, Washington Parks R, Cecchinato V, Fukumoto R, Nicot C, and **Franchini G**: Suppression of HTLV-1 Replication by Tax-mediated Re-routing of the p13 Viral Protein to Nuclear Speckles. *Blood.* In press. (VB)

CCR Nanobiology Program - Robert Blumenthal, Ph.D.

There were no submissions reported this month.

Laboratory of Population Genetics - Kenneth Buetow, Ph.D.

There were no submissions reported this month.

Molecular Discovery Program - R. Andrew Byrd, Ph.D.

Structural Biophysics Laboratory - R. Andrew Byrd, Ph.D.

There were no submissions reported this month.

Molecular Targets Laboratory - James McMahon, Ph.D.

There were no submissions reported this month.

Chemical Biology Laboratory - Joel Schneider, Ph.D.

Johannessen L, Remsberg J, Gaponenko V, Adams KM, **Barchi Jr JJ**, Tarasov SG, Jiang S, and Tarasova NI: Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors. *Chem Bio Chem*. 12: 914-921, 2011. (CBL)

Smith DJ, Yap GPA, **Kelley JA**, and **Schneider JP**: Enhanced Stereoselectivity of a Cu(II) complex chiral auxiliary in the synthesis of Fmoc-L- gamma-carboxyglutamic acid. *J Org Chem*. 76: 1513-1520, 2011. (CBL)

Radiation Oncology Branch - Kevin Camphausen, M.D.

Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, **Citrin DE**, Heiss JD, **Camphausen K**, and **Rosenberg SA**: Surgical management of melanoma brain metastases in patients treated with immunotherapy. *J Neurosurg*. In press. (ROB)

Smith B, Lyakhov I, Loomis K, Needle D, Baxa U, Yavlovich A, **Capala J**, **Blumenthal R**, and Puri A: Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). *J Control Release*. In press. (ROB)

Song HA, Kang CS, Baidoo KE, Milenic DE, Chen Y, Dai A, **Brechbiel MW**, and Chong HS: Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α -Radioimmunotherapy Applications. *Bioconjug Chem*. In press. (ROB)

Nwe K, Milenic D, Bryant LH, Regino CA, and **Brechbiel MW**: Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI. *J Inorg Biochem*. 105(5): 722-727, 2011. (ROB)

Shankavaram UT, Bredel M, Burgan WE, Carter D, **Tofilon P**, and **Camphausen K**: Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. *J Cell Mol Med*. In press. (ROB)

Steeg PS, **Camphausen KA**, and Smith QR: Brain metastases as preventive and therapeutic targets. *Nat Rev Cancer*. 11(5): 352-363, 2011. (ROB)

Rosenberg SA, **Yang JC**, Sherry RM, **Kammula US**, Hughes MS, Phan GQ, **Citrin DE**, **Restifo NP**, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, and Dudley ME: Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy. *Clin Cancer Res*. In press. (ROB)

Shankavaram UT, Bredel M, Burgan WE, Carter D, **Tofilon P**, and **Camphausen K**: Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. *J Cell Mol Med*. In press. (ROB)

Molecular Imaging Program - Peter Choyke, M.D.

Longmire MR, Ogawa M, **Choyke PL**, and **Kobayashi H**: Biologically Optimized Nanosized Molecules and Particles: More than Just Size. *Bioconjug Chem*. In press. (MIP)

Kojima C, Turkbey B, Ogawa M, Bernardo M, Regino CA, Bryant Jr LH, **Choyke PL**, Kono K, and **Kobayashi H**: Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. *Nanomedicine*. In press. (MIP)

Kobayashi H, Longmire MR, Ogawa M, and **Choyke PL**: Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. *Chem Soc Rev*. In press. (MIP)

Laboratory of Cancer Prevention - Nancy Colburn, Ph.D.

Grkovic T, Blees JS, **Colburn NH**, Schmid T, Thomas CL, Henrich CJ, **McMahon JB**, and **Gustafson KR**: Cryptocaryols A-H α -Pyrone-Containing 1,3-Polyols from *Cryptocarya* sp. Implicated in Stabilizing the Tumor Suppressor Pcd4. *J. Nat. Prod*. In press. (LCP)

Crea F, Duhagon MA, **Farrar WL**, and Danesi R: Pharmacogenomics and cancer stem cells: a changing landscape? *Trend Pharmacol Sci*. In press. (LCP)

Smith AM, Qualls JE, O'Brien K, Balouzian L, **Johnson PF**, Schultz-Cherry S, Smale ST, and Murray PJ: A distal enhancer in *Il12b* is the target of transcriptional repression by the STAT3 pathway and requires the B-ZIP protein NFIL-3. *J. Biol. Chem*. In press. (LCP)

Schedrina VA, Kabil H, Vorbruggen G, Lee BC, Turanov AA, Hirosewa-Takamori J, Harshman LG, **Hatfield DL**, and Gladyshev VN: Analyses of fruit flies that do not express selenoproteins or express a mouse selenoprotein, methionine sulfoxide reductase B1, reveal a role of selenoproteins in stress resistance. *J. Biol. Chem*. In press. (LCP)

Xu X, Turanov AA, Carlson BA, Yoo MH, Everley RA, Nandakumar R, Sorokina I, Gygi SP, Gladyshev, VN, and **Hatfield DL**: Targeted insertion of cysteine by decoding UGA codons with mammalian selenocystein machinery. *Proc. Natl. Acad. Sci.* 107(50): 21430-21434, 2011. (LCP)

Neuro-Oncology Branch - Howard Fine, M.D.

There were no submissions reported this month.

Medical Oncology Branch - Giuseppe Giaccone, M.D., Ph.D.

Mannel RS, Brady MF, **Kohn EC**, Hanjani P, Hiura M, Lee R, DeGeest K, Cohn DE, Monk BJ, and Michael H: GOG 175: A randomized phase III trial of IV Carboplatin (AUC 6) and paclitaxel 175 mg/m² q 21 days x 3 courses followed by observation versus maintenance low dose paclitaxel 40 mg/m²/wk in patients with early stage ovarian carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol*. In press. (MOB)

Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, **Kohn EC**, Leo GD, and Alessandro R: Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. *Cancer Lett*. 300: 205-214, 2011. (MOB)

Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli K, Bateman NW, Allard J, Miller C, Sun M, Flint MS, Zahn C, Oliver J, Banerjee S, Litz T, Parwani A, Sandburg G, Rose S, Becich M, Berchuck A, **Kohn EC**, Risinger J, and Conrads TP: Proteomic analysis of stage I endometrial cancer tissue: Identification of proteins associated with oxidative processes and inflammation. *Gynecol Oncol*. In press. (MOB)

Lee J-M, Han JJ, Altwerger G, and **Kohn EC**: Proteomics and biomarkers in clinical trials for drug development. *J Proteomics*. In press. (MOB)

Hoskins E, Elmasri W, Rodriguez-Canales J, Clair T, Hewitt SM, Rasool N, and **Kohn EC**: Paracrine consequences of SLPI secretion: Upregulation of MMP-9 transcription and secretion in ovarian cancer cells. *Gynecol Oncol*. In press. (MOB)

Robey RW, Lin B, Qiu J, Chan LL, and **Bates SE**: Rapid detection of ABC transporter interaction: Potential utility in pharmacology. *J Pharmacol Toxicol Methods*. 63(3): 217-222, 2011. (MOB)

Zhang C, Elkahoul AG, Liao H, Delaney S, Saber B, Morrow B, Gills J, Hollander MC, Prendergast GC, and **Dennis PA**: Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. *Mol Cancer Ther*. In press. (MOB)

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, **Figg WD**, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, and Kantoff PW: SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. *J Clin Oncol*. In press. (MOB)

Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, **Figg WD**, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, and Grant S: Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. *Clin Cancer Res.* 17(10): 3388-3397, 2011. (MOB)

Gao R, Reece K, Sissung T, Reed E, Price DK, and **Figg WD**: The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. *Mutat. Res. Netherlands.* 708: 21-27, 2011. (MOB)

Peer CJ, Sissung TM, and **Figg WD**: CHIP and gp78-mediated ubiquitination of CYP3A4. *Cancer Biol. Ther. USA.* 11: 6, 2011. (MOB)

Franke RM, Lancaster CS, Peer CJ, Gibson A, Kosloske AM, Orwick SJ, Mathijssen RH, **Figg WD**, Baker SD, and Sparreboom A: Dependence of Erythromycin Metabolism on ABCC2 (MRP2) Transport Function. *Clin. Pharmacol. Therap.* In press. (MOB)

Pressler HM, Sissung TM, Marino M, Venzon D, Price DK, and **Figg WD**: Expression of OATP family members in normal and human tissues and malignancies: potential cancer biomarkers. *PLoS One.* In press. (MOB)

Jain L, Woo S, **Dahut WL**, **Kohn EC**, **Kummar S**, **Yarchoan R**, **Giaccone G**, Venitz J, and **Figg WD**: Population Pharmacokinetics of Sorafenib in Patients with Solid Tumors using Clinical and Pharmacogenetic Patient Covariates. *Br. J. Clin. Pharmacol.* In press. (MOB)

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EE, Stanczyk FZ, Reichardt JKV, Tang L, Neuhaus ML, Santella RM, **Figg WD**, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A: Serum Estrogen Levels and Prostate Cancer Risk in the Prostate Cancer Prevention Trial: A Nested Case-Control Study. *Cancer Causes and Control.* In press. (MOB)

Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, **Kleiner DE**, Pletcher JM, **Figg WD**, Yovandich JL, and Creekmore SP: Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. *Blood.* 117(18): 4787-4795, 2011. (MOB)

Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, **Landgren O**, and **Giaccone G**: A population-based assessment of mortality and morbidity patterns among patients with thymoma. *Int J Cancer.* 128(11): 2688-2694, 2011. (MOB)

Force J, Rajan A, Dombi E, Steinberg SM, and **Giaccone G**: Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol*. In press. (MOB)

Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, **Trepel J**, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, and Loehrer Sr PJ: Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors. *J Clin Oncol*. 29(15): 2052-2059, 2011. (MOB)

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, and **Giaccone G**: American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. *J Clin Oncol*. 29(15): 2121-2127, 2011. (MOB)

Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, and **Giaccone G**: Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 17(9): 2638-2645, 2011. (MOB)

Laboratory of Metabolism - Frank Gonzalez, Ph.D.

Park J-E, Erikson RL, and **Lee KS**: Feed-forward mechanism of converting biochemical cooperativity to mitotic processes at the kinetochore plate. *Proc. Natl. Acad. Sci. USA*. In press. (LM)

Kang YH, Park CH, Soung N-K, Bang JK, Kim BY, and **Lee KS**: Mammalian Polo-like Kinase 1-dependent Regulation of the PBIP1-CENP-Q Complex at Kinetochores. *J. Biol. Chem*. In press. (LM)

Laboratory of Cell Biology - Michael Gottesman, M.D.

Ohnuma S, Chufan E, Nandigama K, Jenkins L, Durell S, **Appella E**, Sauna ZE, and **Ambudkar SV**: Inhibition of the multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonyl 5'-adenosine: Evidence for an ATP analog that interacts with both drug-substrate- and nucleotide-binding-sites. *Biochemistry*. In press. (LCB)

Experimental Transplantation and Immunology Branch - Ronald Gress, M.D.

There were no submissions reported this month.

Laboratory of Receptor Biology and Gene Expression - Gordon Hager, Ph.D.

Hakim O, Sung MH, Voss TC, John S, Splinter E, Sabo PJ, Thurman RE, Stamatoyannopoulos JA, de Laat W, and **Hager GL**: Diverse gene reprogramming events occur in the same spatial clusters of distal regulatory elements. *Genome Res.* 21: 697-706, 2011. (LRBGE)

Laboratory of Human Carcinogenesis - Curtis Harris, M.D.

There were no submissions reported this month.

HIV Drug Resistance Program - Stephen Hughes, Ph.D.

HIV DRP Host Virus Interaction Branch - Stephen Hughes, Ph.D.

There were no submissions reported this month.

Retroviral Replication Laboratory - Stephen Hughes, Ph.D.

Bindewald E, Wendeler M, Legiewicz M, Bona MK, Wang Y, Pritt MJ, **Le Grice SFJ**, and **Shapiro BA**: Correlating SHAPE signatures with 3D RNA structures. *RNA.* 17: 1688-1696, 2011. (RRL)

Chung S, Himmel DM, Jiang J-K, Wojtak K, Bauman JD, Rausch JD, Wilson JA, **Beutler JA**, Thomas CJ, Arnold E, and **Le Grice SFJ**: Synthesis, activity and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. *J. Med. Chem.* In press. (RRL)

Dash C, Ahmadibeni Y, Hanley JM, Pandhar J, Gotte M, **Le Grice SFJ**, and Parang K: Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside β -triphosphates. *Bioorg. Med. Chem. Lett.* 21: 3519-3522, 2011. (RRL)

Lu W, Salzwedel K, Wang D, Chakravarty S, **Freed EO**, Wild CT, and Li F: A single polymorphism in HIV-1 subtype C SP-1 is sufficient to confer natural resistance to the maturation inhibitor, bevirimat. *Antimicrob. Agents Chemother.* 55: 3324-3329, 2011. (RRL)

Sfanos KS, Aloia AL, Hicks JL, Esopi DM, Steranka JP, Shao W, Sanchez-Martinez S, Yegnasubramanian S, Burns KH, **Rein A**, and De Marzo AM: Identification of replication competent murine gammaretrovirus in commonly used prostate cancer cell lines. *PLoS One.* 6: e20874, 2011. (RRL)

Laboratory of Comparative Carcinogenesis - Larry Keefer, Ph.D.

Tsihlis ND, Oustwani CS, Vavra AK, Jiang Q, **Keefer LK**, and Kibbe MR: Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of Ubch10. *Cell Biochem. Biophys.* 60: 89-97, 2011. (LCC)

Nandurdikar RS, **Keefe LK**, and Saavedra JE: Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO. Chem. Commun. In press. (LCC)

Vavra AK, Havelka GE, Martinez J, Lee VR, Fu B, Jiang Q, **Keefe LK**, and Kibbe MR: Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. Nitric Oxide. In press. (LCC)

Qu W, Cheng L, Dill AL, Saavedra JE, Hong SY, **Keefe LK**, and Waalkes MP: Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1. Chem. Biol. Interact. In press. (LCC)

Cell and Cancer Biology Branch - Kathleen Kelly, Ph.D.

There were no submissions reported this month.

Urologic Oncology Branch - W. Marston Linehan, M.D.

Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, **Merino M**, Hong JA, **Schrump DS**, **Srinivasan R**, **Linehan WM**, Tian X, Lerman MI, and Childs RW: Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene. In press. (UOB)

Laboratory of Cellular Oncology - Douglas Lowy, M.D.

There were no submissions reported this month.

Pediatric Oncology Branch - Crystall Mackall, M.D.

There were no submissions reported this month.

Genetics Branch - Paul Meltzer, M.D., Ph.D.

Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, and Cao L: Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response. Clin. Cancer Res. 17: 3181-3192, 2011. (GB; PI: **Meltzer PS**)

Huppi K, Pitt J, Wahlberg B, and **Caplen NJ**: Genomic instability and mouse microRNAs. Toxicol. Mech. Methods. 21: 325-333, 2011. (GB)

Valenzuela MS, Chen Y, Davis S, Yang F, Walker RL, Bilke S, Lueders J, Martin MM, **Aladjem MI**, Massion PP, and **Meltzer PS**: Preferential localization of human origins of DNA replication at the 5'-ends of expressed genes and at evolutionarily conserved DNA sequences. *PLoS One*. 6(5): e17308, 2011. (GB)

Killian JK, Bilke S, Davis S, Walker RL, Jaeger E, Killian MS, Waterfall JJ, Bibikova M, Fan J-B, Smith Jr WI, and **Meltzer PS**: A Methyl-Deviator Epigenotype of Estrogen Receptor-Positive Breast Carcinoma Is Associated with Malignant Biology. *Am J Pathol*. In press. (GB)

Meltzer P: Melanoma researchers have a reason to GRIN: melanoma yields more of its secrets to exome sequencing. *Pigment Cell and Melanoma Res*. In press. (GB)

Gaiser T, Camps J, Meinhardt S, Wangsa D, Nguyen QT, Varma S, Dittfeld C, Kunz Schughart LA, Kemmerling R, Becker MR, Heselmeyer-Haddad K, and **Ried T**: Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer Cells. *Am J Pathol*. 178(4): 1478-1488, 2011. (GB)

Lab of Cancer Biology & Genetics - Glenn Merlino, PhD and Stuart Yuspa, MD
There were no submissions reported this month.

Radiation Biology Branch - James Mitchell, Ph.D.
There were no submissions reported this month.

Laboratory of Cell and Developmental Signaling - Debbie Morrison, Ph.D.
There were no submissions reported this month.

Laboratory of Pathology - J. Carl Oberholtzer, M.D., Ph.D.

Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, Gonzalez-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Brazier R, Rosenwald A, Lenz G, Wright G, **Jaffe ES**, **Staudt L**, Jares P, Lopez-Guillermo A, and Campo E: High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Haematologica*. In press. (LP)

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, **Kleiner DE**, Hoofnagle JH, and Robuck PR: Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA*. 305(16): 1659-1668, 2011. (LP)

Sanyal AJ, Brunt EM, **Kleiner DE**, Kowdley K, Chalasani N, Lavine J, Ratziu V, and McCullough A: Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology*. In press. (LP)

Shao H, Xi L, **Raffeld M**, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, **Pittaluga S**, and **Jaffe ES**: Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic/small lymphocytic lymphoma: A study of 7 cases. *Mod. Pathol.* In press. (LP)

Laboratory of Genomic Diversity - Stephen O'Brien, Ph.D.

There were no submissions reported this month.

Lab of Molecular Biology - Ira Pastan, M.D. and Susan Gottesman, Ph.D.

De Lay N and **Gottesman S**: Role of polynucleotide phosphorylase in sRNA function in *Escherichia coli*. *RNA*. 17: 1172-1189, 2011. (LMB)

Genest O, Hoskins JR, Camberg JL, Doyle SM, and **Wickner S**: Heat shock protein 90 from *Escherichia coli* collaborates with the DnaK chaperone system in client protein remodeling. *Proc. Natl. Acad. Sci. USA*. 108: 8206-8211, 2011. (LMB)

Cancer and Developmental Biology Laboratory - Alan Perantoni, Ph.D.

Chalamalasetty R, Dunty WC, Biris KK, Ajima R, Iacovino M, Beisaw A, Feigenbaum K, Chapman DL, Yoon JK, Kyba M, and **Yamaguchi TP**: The Wnt3a/bcatenin target gene *Mesogenin1* controls the segmentation clock by activating a Notch signaling program. *Nature Commun.* In press. (CDBL)

Stefater III JA, Lewkowich I, Rao S, Marrigi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkenin JD, Williams BO, Willis-Karp M, Pollard J, **Yamaguchi TP**, Ferrara N, Gerhardt H and Lang RA: Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. *Nature*. In press. (CDBL)

Mackem S and **Lewandoski M**: Development: Limb cells don't tell time. *Science*. 332: 1038-1039, 2011. (CDBL)

Laboratory of Molecular Pharmacology - Yves Pommier, M.D., Ph.D.

Luna A, Karac EI, Sunshine M, Chang L, **Nussinov R**, **Aladjem MI**, and **Kohn KW**: A formal MIM specification and tools for the common exchange of MIM diagrams: an XML-based format, an API, and a validation method. *BMC Bioinformatics*. 12: 167, 2011. (LMP)

Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, **Stommel JM**, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, and Kimmelman AC: Pancreatic cancers require autophagy for tumor growth. *Genes Dev.* 25: 717-729, 2011. (LMP)

Valenzuela MS, Chen Y, Davis S, Yang F, Walker RL, Bilke S, Lueders J, Martin MM, **Aladjem MI**, Massion PP, and **Meltzer PS**: Preferential localization of human origins of DNA replication at the 5'-ends of expressed genes and at evolutionarily conserved DNA sequences. *PLoS One.* 6: e17308, 2011. (LMP)

Martin OA, Redon CE, Nakamura AJ, Dickey JS, Georgakilas AG, and **Bonner WM**: Systemic DNA damage related to cancer. *Cancer Res.* 71: 3437-3441, 2011. (LMP)

Baird BJ, Dickey JS, Nakamura AJ, Redon CE, Parekh P, Griko YV, Aziz K, Georgakilas AG, **Bonner WM**, and Martin OA: Hypothermia postpones DNA damage repair in irradiated cells and protects against cell killing. *Mutat. Res.* 711: 142-149, 2011. (LMP)

Bergmann JH, Rodriguez MG, Martins NM, Kimura H, Kelly DA, Masumoto H, **Larionov V**, Jansen LE, and Earnshaw WC: Epigenetic engineering shows H3K4me2 is required for HJURP targeting and CENP-A assembly on a synthetic human kinetochore. *EMBO J.* 30: 328-340, 2011. (LMP)

Surgery Branch - Steven Rosenberg, M.D., Ph.D.

There were no submissions reported this month.

Mammary Biology & Tumorigenesis Lab – David Salomon, Ph.D. (Acting Lab Chief)

There were no submissions reported this month.

Laboratory of Cellular and Molecular Biology - Larry Samelson, M.D.

There were no submissions reported this month.

Laboratory of Tumor Immunology and Biology - Jeffrey Schlom, Ph.D.

There were no submissions reported this month.

Experimental Immunology Branch - Alfred Singer, M.D.

There were no submissions reported this month.

Gene Regulation and Chromosome Biology Lab - Jeffrey Strathern, Ph.D.

There were no submissions reported this month.

Laboratory of Experimental Carcinogenesis - Snorri Thorgeirsson, M.D., Ph.D.

There were no submissions reported this month.

Cancer and Inflammation Program - Giorgio Trinchieri, M.D.

Laboratory of Molecular Immunoregulation - Joost Oppenheim, M.D.

Qi J, Buzas K, Fan H, Cohen JI, Wang K, Mont E, **Klinman D**, **Oppenheim JJ**, and **Howard OMZ**: Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. *J Immunol.* 186: 6417-6426, 2011. (LMI)

Laboratory of Experimental Immunology - Giorgio Trinchieri, M.D.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff Jr CL, Song W, Stroncek DF, Tahara H, Thurin M, **Trinchieri G**, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, **Khleif S**, Fox BA, and Disis ML: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. *Clin Cancer Res.* 17: 3064-3076, 2011. (LEI)

Kuniholm MH, Gao X, Xue X, Kovacs A, Marti D, Thio CL, Peters MG, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Young MA, Strickler HD, and **Carrington M**: The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women. *J Infect Dis.* 203: 1807-1814, 2011. (LEI)

Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, and **Wiltrout RH**: mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. *Cancer Res.* 71: 4074-4084, 2011. (LEI)

Liu B, Willette-Brown J, Liu S, Chen X, Fischer SM, and **Hu Y**: IKK α represses a network of inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a dose-dependent manner in the skin. *Cell Death Differ.* 18: 1854-1864, 2011. (LEI)

Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Mai PL, Greene MH, Piedmonte M, Rubinstein WS, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer HE, Van Roozendaal CE, Caldes T, Perez-Segura P, Jakubowska A, Lubinski J, Huzarski T, Blecharz P, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Barkardottir RB, Montagna M, D'Andrea E, Devilee P, Olopade OI, Neuhausen SL, Peissel B, Bonanni B, Peterlongo P, Singer CF, Rennert G, Lejbkovicz F, Andrulis

IL, Glendon G, Ozcelik H, Toland AE, Caligo MA, Beattie MS, Chan S, Domchek SM, Nathanson KL, Rebbeck TR, Phelan C, Narod S, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Hansen TV, Osorio A, Benitez J, Durán M, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Eeles R, Izatt L, Paterson J, Brewer C, Hodgson S, Morrison PJ, Porteous M, Walker L, Rogers MT, Side LE, Godwin AK, Schmutzler RK, Wappenschmidt B, Laitman Y, Meindl A, Deissler H, Varon-Mateeva R, Preisler-Adams S, Kast K, Venat-Bouvet L, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF, Klein RJ, Daly MJ, Friedman E, **Dean M**, Clark AG, Altshuler DM, Antoniou AC, Couch FJ, Offit K, and Gold B: Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Hum Genet.* 130: 685-699, 2011. (LEI)

McKay GJ, Silvestri G, Chakravarthy U, Dasari S, Fritsche LG, Weber BH, Keilhauer CN, Klein ML, Francis PJ, Klaver CC, Vingerling JR, Ho L, De Jong PT, **Dean M**, Sawitzke J, Baird PN, Guymer RH, Stambolian D, Orlin A, Seddon JM, Peter I, Wright AF, Hayward C, Lotery AJ, Ennis S, Gorin MB, Weeks DE, Kuo CL, Hingorani AD, Sofat R, Cipriani V, Swaroop A, Othman M, Kanda A, Chen W, Abecasis GR, Yates JR, Webster AR, Moore AT, Seland JH, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Vioque J, Young IS, Fletcher AE, and Patterson CC: Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. *Am J Epidemiol.* In press. (LEI)

Barao I, Alvarez M, Ames E, Orr MT, Stefanski HE, Blazar BR, Lanier LL, **Anderson SK**, Redelman D, and Murphy WJ: Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independent of MHC. *Blood.* 117: 7032-7041, 2011. (LEI)

Dermatology Branch - Mark Udey, M.D., Ph.D.

There were no submissions reported this month.

Mouse Cancer Genetics Program - Terry Van Dyke, Ph.D.

There were no submissions reported this month.

Metabolism Branch - Thomas Waldmann, M.D.

There were no submissions reported this month.

Laboratory of Protein Dynamics & Signaling - Allan Weissman, M.D.

There were no submissions reported this month.

Macromolecular Crystallography Laboratory - Alexander Wlodawer, Ph.D.

There were no submissions reported this month.

Laboratory of Biochemistry and Molecular Biology - Carl Wu, Ph.D.

Dayani Y, Simchen G, and **Lichten M**: Meiotic Recombination Intermediates are Resolved with Minimal Crossover Formation during Return-to-Growth, an Analogue of the Mitotic Cell Cycle. *PLoS Biol.* 7(5): e1002083, 2011. (LBMB)

HIV and AIDS Malignancy Branch - Robert Yarchoan, M.D.

Ziegelbauer JM: Functions of Kaposi's sarcoma-associated herpesvirus microRNAs. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*. In press. (HAMB)

Basic Research Laboratory

There were no submissions reported this month.

Emeritus Scientists

Victor Marquez

Huang WY, Yang PM, Chang YF, **Marquez VE**, and Chen CC: Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. *Biochemical Pharmacol.* 81: 510-517, 2011. (CBL)

Terrazas M, Ocampo SM, Perales JC, **Marquez VE**, and Eritja R: Effect of North Bicyclo[3.1.0]hexane 2'-Deoxy-pseudosugars on RNA interference: A novel class of siRNA modification. *Chem Bio Chem.* 12: 1056-1065, 2011. (CBL)